Despite the many applications of CN Bio’s FDA-characterized PhysioMimix® Multi-chip Liver-12 plate, which has successfully supported a regulatory submission, industry adoption remained incremental, with throughput being a limiting factor.

The PhysioMimix® Liver-48 plate poster from MPS 2024 demonstrates how our PhysioMimix Multi-chip Liver-48 plate retains an SBS-standard footprint and maintain Liver MPS functionality, whilst increasing throughput. The Liver-48 plate was tested for its ability to produce viable and functional microtissues with the same donor combination of hepatocytes and Kupffer cells (as the PhysioMimix Multi-Chip Liver-12 plates), representing the liver sinusoidal structure, QC metrics, and the Liver-48 plates’ utility in assessing hepatotoxicity.

By miniaturizing each Liver chip, 48 tissues can be cultured per plate (a total of 144 chips per PhysioMimix Single-organ HT System); increasing the throughput to enable more drug candidates, replicates and controls to be tested over a broader range of concentrations, and conditions for a fast, robust and cost-effective understanding of human drug safety profiles earlier in the drug development pipeline.